Adma Biologics Inc (ADMA)

NASD · Healthcare · Biotechnology · USA

Adma Biologics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

ADMA Biologics manufactures and markets specialty biologics derived from blood plasma for treating immunodeficient patients at risk for infections. The company produces three FDA-approved products: ASCENIV and BIVIGAM for primary immunodeficiency, and Nabi-HB for hepatitis B exposure. It operates a plasma fractionation facility in Florida and owns plasma collection centers that supply raw materials and serve third-party customers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Adma Biologics Inc stock.

Our verdict on ADMA

Undervalued: intrinsic value $17.29 per share, market price $13.63, margin of safety 21.2% (as of 2026-11-17).

Discounting its cash flows at 8.6% (average of 3 methods) values the shares at $17.29; the price of $13.63 is 21% below that value, and 79% of that value comes from beyond year five.

ETFs with the most weight in ADMA

17 more funds hold it; the full list is part of the paid plan.

More on ADMA

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ADMA in Biotechnology

14 more in this industry show a wider margin of safety.

Is ADMA undervalued or overvalued?

ADMA is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 8.6% (average of 3 methods) values the shares at $17.29; the price of $13.63 is 21% below that value, and 79% of that value comes from beyond year five.

What is the intrinsic value of ADMA?

$17.29 per share (as of the 2026-11-17 close), against a market price of $13.63. That is a margin of safety of 21.2%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.